Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Trial of CD70-Targeted Immuno-PET/CT-Directed Treatment Holiday for Metastatic Clear Cell Renal Cell Carcinoma With IMDC Favorable or Intermediate Risk

NCT07615348 is registered in ClinicalTrials.gov with Jinling Hospital, China as lead sponsor.

NCT NCT07615348
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07615348 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Trial of CD70-Targeted Immuno-PET/CT-Directed Treatment Holiday for Metastatic Clear Cell Renal Cell Carcinoma With IMDC Favorable or Intermediate Risk
Lead sponsor
Jinling Hospital, China
Phase
Phase 2
Overall status
Recruiting
Start date
June 16, 2026
Completion date
August 10, 2029
Enrollment
75 (estimated)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

metastatic clear cell renal cell carcinoma